The effect of empagliflozin on reduction of cardiovascular complication after PCI
Phase 3
- Conditions
- Type 2 diabetes mellitus.Diabetes mellitus due to underlying condition
- Registration Number
- IRCT20210612051550N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with definitive diagnosis of diabetes mellitus type 2 (HbA1c= 6.8%)
Consent to participate in the study
Exclusion Criteria
Diabetic ketoacidosis
Urinary and genital infections
Type 1 diabetes
Severe liver failure
Existence of malignancy and cancer
eGFR 30 < ml/min
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiovascular events (MACE). Timepoint: During 6 month follow up after PCI. Method of measurement: Based on symptoms and clinical examinations, laboratory parameters and echocardiographic assessment.
- Secondary Outcome Measures
Name Time Method